BRIEF-Gilead requests FDA pull orphan drug designation from potential coronavirus drug

Gilead Sciences Inc: * Says requested the U.S. FDA rescind the orphan drug designation it was granted for potential coronavirus drug remdesivir

* Says waiving all benefits that accompany orphan drug designation for remdesivir * Says confident that it can maintain an expedited timeline in seeking regulatory review of remdesivir Further company coverage: